Cardiovascular diseases and CVD-related risk factor prevalence in NENC Deep End practices compared with NENC non-Deep End and England practices
| Risk factors | Deep End practices | Non-Deep End practices | 95% CI mean difference (DE vs non-DE) | England | 95% CI mean difference (DE vs England) | |||
| Mean (SD) | Range | Mean (SD) | Range | Mean (SD) | Range | |||
| Smoking prevalence (%) | ||||||||
| Register 2019/2020 | 24.5 (4.9) | (17.8, 39.3) | 16.3 (4.5) | (4.7, 27.5) | (6.5 to 9.8)** | 16.5 (–) | (6.3 to 9.7)** | |
| Register 2020/2021 | 23.8 (4.5) | (17.6, 37.5) | 15.8 (4.4) | (4.5, 26.4) | (6.4 to 9.6)** | 15.9 (–) | (6.3 to 9.5)** | |
| 95% CI mean difference | (−2.9 to 1.6) | (−1.3 to 0.3) | ||||||
| HYP | ||||||||
| Register (n) 2019/2020 | 1131 (856) | (11, 4504) | 1373 (717) | (164, 3530) | (−506 to 22) | 1279 (868) | (0, 11 720) | (−440 to 145) |
| Register (n) 2020/2021 | 1136 (876) | (14, 4500) | 1392 (861) | (176, 8858) | (−567 to 54) | 1287 (889) | (0, 11 886) | (−450 to 149) |
| 95% CI mean difference | (−414 to 424) | (−120 to 159) | (−22 to 38) | |||||
| Prevalence (%) 2019/2020 | 14.2 (4.3) | (0.9, 21.2) | 16.6 (3.2) | (1.0, 29.3) | (−3.6 to −1.2)** | 14.4 (4.1) | (0, 87.9) | (−1.5 to 1.2) |
| Prevalence (%) 2020/2021 | 13.9 (4.1) | (1.0, 20.7) | 16.5 (3.2) | (1.0, 28.8) | (−3.7 to −1.3)** | 14.2 (4.0) | (0, 61.3) | (−1.6 to 1.1) |
| 95% CI mean difference | (−2.3 to 1.7) | (−0.7 to 0.4) | (−0.3 to 0.0) | |||||
| AF | ||||||||
| Register (n) 2019/2020 | 143 (112) | (0, 539) | 202 (112) | (12, 634) | (−99 to −18)* | 186 (150) | (0, 1445) | (−94 to 7) |
| Register (n) 2020/2021 | 146 (122) | (0, 517) | 206 (113) | (14, 1346) | (−107 to −12)* | 189 (155) | (0, 1424) | (−95 to 9) |
| 95% CI mean difference | (−53 to 60) | (−17 to 26) | (−2 to 8) | |||||
| Prevalence (%) 2019/2020 | 1.7 (0.6) | (0, 2.7) | 2.4 (0.6) | (0.1, 4.2) | (−0.9 to −0.5)** | 2.0 (1.0) | (0, 28.7) | (−0.6 to 0.1) |
| Prevalence (%) 2020/2021 | 1.7 (0.6) | (0, 2.7) | 2.4 (0.6) | (0.1, 4.3) | (−0.9 to −0.5)** | 2.0 (1.1) | (0, 28.2) | (−0.7 to 0.1) |
| 95% CI mean difference | (−0.3 to 0.3) | (−0.1 to 0.1) | (0.0 to 0.0) | |||||
| CHD | ||||||||
| Register (n) 2019/2020 | 302 (221) | (3, 1078) | 348 (192) | (25, 977) | (−117 to 24) | 281 (204) | (0, 2392) | (−48 to 90) |
| Register (n) 2020/2021 | 301 (230) | (3, 1067) | 349 (231) | (24, 2447) | (−131 to 35) | 282 (209) | (0, 2447) | (−51 to 90) |
| 95% CI mean difference | (−110 to 109) | (−36 to 39) | (−6 to 8) | |||||
| Prevalence (%) 2019/2020 | 3.8 (1.3) | (0.3, 6.4) | 4.2 (0.9) | (0.2, 6.2) | (−0.7 to 0.0)* | 3.2 (1.2) | (0, 31.1) | (0.2 to 1.1)* |
| Prevalence (%) 2020/2021 | 3.7 (1.2) | (0.2, 5.9) | 4.1 (0.9) | (0.1, 6.2) | (−0.7 to −0.1)* | 3.1 (1.2) | (0, 30.0) | (0.2 to 1.0)* |
| 95% CI mean difference | (−0.7 to 0.5) | (−0.2 to 0.1) | (−0.1 to 0.0) | |||||
| HF | ||||||||
| Register (n) 2019/2020 | 86 (82) | (1, 405) | 104 (73) | (4, 471) | (−45 to 8) | 81 (70) | (0, 1124) | (−19 to 29) |
| Register (n) 2020/2021 | 91 (92) | (1, 410) | 106 (92) | (5, 1047) | (−48 to 18) | 84 (74) | (0, 1047) | (−18 to 32) |
| 95% CI mean difference | (−37 to 47) | (−13 to 16) | (0 to 5) | |||||
| Prevalence (%) 2019/2020 | 1.0 (0.5) | (0.1, 2.2) | 1.2 (0.5) | (0, 3.1) | (−0.4 to 0) | 0.9 (0.5) | (0, 13.4) | (0 to 0.3) |
| Prevalence (%) 2020/2021 | 1.1 (0.6) | (0.1, 2.8) | 1.2 (0.5) | (0, 2.9) | (−0.3 to 0) | 0.9 (0.5) | (0, 12.1) | (0 to 0.3) |
| 95% CI mean difference | (−0.2 to 0.3) | (−0.1 to 0.1) | (0.0 to 0.0) | |||||
| LVSD | ||||||||
| Register (n) 2019/2020 | 45 (51) | (0, 259) | 59 (50) | (3, 309) | (−31 to 5) | 33 (39) | (0, 532) | (0 to 26) |
| Register (n) 2020/2021 | 51 (62) | (0, 265) | 60 (60) | (3, 625) | (−31 to 12) | 36 (43) | (0, 670) | (0 to 29)* |
| 95% CI mean difference | (−22 to 33) | (−8 to 11) | (2 to 4) | |||||
| Prevalence (%) 2019/2020 | 0.6 (0.4) | (0, 1.6) | 0.7 (0.4) | (0, 2.3) | (−0.3 to 0) | 0.4 (0.3) | (0, 3.4) | (0.1 to 0.3)** |
| Prevalence (%) 2020/2021 | 0.6 (0.5) | (0, 2.2) | 0.7 (0.4) | (0, 2.1) | (−0.2 to 0.1) | 0.4 (0.3) | (0, 5.6) | (0.1 to 0.3)** |
| 95% CI mean difference | (−0.2 to 0.2) | (−0.1 to 0.1) | (0.0 to 0.0) | |||||
| PAD | ||||||||
| Register (n) 2019/2020 | 76 (55) | (0, 251) | 77 (45) | (3, 228) | (−17 to 16) | 54 (45) | (0, 747) | (7 to 37)* |
| Register (n) 2020/2021 | 76 (56) | (0, 243) | 76 (51) | (4, 487) | (−19 to 19) | 54 (46) | (0, 720) | (6 to 37)* |
| 95% CI mean difference | (−27 to 27) | (−10 to 7) | (−1 to 2) | |||||
| Prevalence (%) 2019/2020 | 0.9 (0.3) | (0.0, 1.8) | 0.9 (0.3) | (0.0, 2.4) | (−0.1 to 0.1) | 0.6 (0.4) | (0.0, 12.8) | (0.2 to 0.5)** |
| Prevalence (%) 2020/2021 | 0.9 (0.3) | (0.0, 1.7) | 0.9 (0.3) | (0.0, 2.2) | (−0.1 to 0.1) | 0.6 (0.4) | (0.0, 21.6) | (0.2 to 0.5)** |
| 95% CI mean difference | (−0.2 to 0.1) | (−0.1 to 0.0) | (0.0 to 0.0) | |||||
| STIA | ||||||||
| Register (n) 2019/2020 | 162 (125) | (0, 617) | 197 (107) | (19, 529) | (−75 to 4) | 163 (123) | (0, 1385) | (−43 to 40) |
| Register (n) 2020/2021 | 167 (135) | (0, 651) | 200 (127) | (20, 1240) | (−79 to 13) | 166 (128) | (0, 1427) | (−42 to 44) |
| 95% CI mean difference | (−57 to 68) | (−18 to 24) | (−1 to 8) | |||||
| Prevalence (%) 2019/2020 | 2.0 (0.6) | (0.0, 2.9) | 2.4 (0.5) | (0.1, 3.5) | (−0.6 to −0.2)** | 1.8 (0.8) | (0.0, 21.9) | (−0.1 to 0.5) |
| Prevalence (%) 2020/2021 | 2.0 (0.6) | (0.0, 2.9) | 2.3 (0.5) | (0.1, 3.9) | (−0.5 to −0.1)** | 1.8 (0.9) | (0.0, 26.7) | (−0.1 to 0.5) |
| 95% CI mean difference | (−0.3 to 0.3) | (−0.1 to 0.1) | (0.0 to 0.0) | |||||
*P<0.05; **p<0.001.
AF, atrial fibrillation; CHD, coronary heart disease; CVD, cardiovascular disease; DE, Deep End; HF, heart failure; HYP, hypertension; LVSD, left ventricular systolic dysfunction; NENC, North East and North Cumbria; PAD, peripheral arterial disease; STIA, stroke and transient ischaemic attack.